ZA200900472B - Liquid compositions of calcium acetate - Google Patents

Liquid compositions of calcium acetate

Info

Publication number
ZA200900472B
ZA200900472B ZA200900472A ZA200900472A ZA200900472B ZA 200900472 B ZA200900472 B ZA 200900472B ZA 200900472 A ZA200900472 A ZA 200900472A ZA 200900472 A ZA200900472 A ZA 200900472A ZA 200900472 B ZA200900472 B ZA 200900472B
Authority
ZA
South Africa
Prior art keywords
calcium acetate
liquid compositions
individual
sweetener
administering
Prior art date
Application number
ZA200900472A
Other languages
English (en)
Inventor
Stephen C Tarallo
Original Assignee
Lyne Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38957385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200900472(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lyne Lab filed Critical Lyne Lab
Publication of ZA200900472B publication Critical patent/ZA200900472B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200900472A 2006-07-21 2009-01-21 Liquid compositions of calcium acetate ZA200900472B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83209306P 2006-07-21 2006-07-21

Publications (1)

Publication Number Publication Date
ZA200900472B true ZA200900472B (en) 2009-11-25

Family

ID=38957385

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900472A ZA200900472B (en) 2006-07-21 2009-01-21 Liquid compositions of calcium acetate

Country Status (18)

Country Link
US (3) US8591938B2 (fr)
EP (2) EP2484352B1 (fr)
JP (1) JP5335674B2 (fr)
KR (1) KR101553719B1 (fr)
CN (2) CN104095838A (fr)
AT (1) ATE547099T1 (fr)
AU (1) AU2007275606B9 (fr)
BR (1) BRPI0714882A2 (fr)
CA (1) CA2658465C (fr)
ES (1) ES2382993T3 (fr)
HK (1) HK1202815A1 (fr)
IL (1) IL196584A0 (fr)
MX (1) MX2009000722A (fr)
NZ (1) NZ574331A (fr)
PL (2) PL2484352T3 (fr)
RU (1) RU2463060C2 (fr)
WO (1) WO2008011126A2 (fr)
ZA (1) ZA200900472B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
ES2382993T3 (es) 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
MX2009008222A (es) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
DK2318028T3 (da) * 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
EP3202459B1 (fr) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Antagonistes d'actriib et dosage et utilisations de ceux-ci pour traiter l'obésité ou le diabète en régulant le taux de graisse corporelle
AU2010315245B2 (en) * 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
JP5766021B2 (ja) * 2010-05-14 2015-08-19 興和株式会社 安定な水性液剤
EP2441436A1 (fr) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Formule de liants de phosphate pour l'extraction simple
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.
US9149529B2 (en) * 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
CN104688681B (zh) * 2015-03-17 2018-01-02 常州康普药业有限公司 利巴韦林口服液及其制备方法
JP6718212B2 (ja) * 2015-08-17 2020-07-08 三菱商事ライフサイエンス株式会社 酢酸カルシウムのえぐ味抑制方法
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
WO2020150460A1 (fr) * 2019-01-18 2020-07-23 Milne Iii Donald A Formulation d'aspirine micronisée
WO2020210608A1 (fr) 2019-04-12 2020-10-15 Biolink Life Sciences, Inc. Concentrés liquides de calcium et de magnésium
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN120078716A (zh) * 2025-02-28 2025-06-03 北京远方通达医药技术有限公司 一种醋酸钙口服溶液的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093710A (en) * 1976-07-07 1978-06-06 Sandoz, Inc. Rapid dissolving effervescent granules
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
JPS6136222A (ja) * 1984-07-26 1986-02-20 Chugai Pharmaceut Co Ltd 高リン酸血症治療剤
GB8629781D0 (en) 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US4870105B1 (en) * 1987-04-07 1998-03-10 Braintree Lab Phosphorus binder
CN1067250A (zh) 1991-05-28 1992-12-23 北京师范大学 桐酸系间苯二酚甲醛树脂的合成方法
DE19528524C2 (de) 1995-08-03 1999-11-11 Hans Dietl Calciumhaltiges Mittel zur intestinalen Phosphatbindung und Verfahren zu seiner Herstellung
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US5833954A (en) * 1996-08-20 1998-11-10 American Dental Association Health Foundation Anti-carious chewing gums, candies, gels, toothpastes and dentifrices
CN1162489A (zh) 1997-02-25 1997-10-22 青岛盖宝特保健品有限公司 酪磷肽钙营养液
CN1067250C (zh) 1997-08-21 2001-06-20 中国人民解放军总装备部后勤部军事医学研究所 中性补钙制剂
US5976507A (en) * 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
US5858333A (en) * 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
DE19917705C1 (de) 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
CN1242963A (zh) 1999-07-26 2000-02-02 李久成 补钙可乐及其制备方法
CN1252278A (zh) 1999-09-16 2000-05-10 冯荣根 锌钙海狸营养品
JP2001204440A (ja) * 2000-01-25 2001-07-31 Mitsukan Group Honsha:Kk カルシウム飲料
US6559187B2 (en) 2000-08-07 2003-05-06 Ranbaxy Signature Llc Liquid formulation of metformin
CN1159993C (zh) 2000-10-26 2004-08-04 李久成 一种强化多元素离子饮料及其制备方法
US6576665B2 (en) * 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
US20030026872A1 (en) * 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
CN1520284A (zh) 2001-05-29 2004-08-11 波切夫斯特鲁姆基督教高等教育大学 包含乙酸钙的厌食组合物
JP2002363105A (ja) * 2001-05-31 2002-12-18 Taiho Yakuhin Kogyo Kk 不快な味のマスキング方法及び内服用液剤
ITMI20011284A1 (it) 2001-06-19 2002-12-19 Salvatore Bilardello Composizione farmaceutica per il trattamento dell'iperfosfatemia
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
GB2395124A (en) 2002-11-16 2004-05-19 Fluid Technologies Plc Palatable microcapsules
RU2005119299A (ru) 2002-11-22 2005-11-20 Фирмениш Са (Ch) Составы для ухода за полостью рта, маскирующие соленый вкус солей
UA86816C2 (uk) * 2004-06-01 2009-05-25 Нікомед Фарма Ас Таблетка для жування, смоктання та ковтання, яка містить кальційвмісну сполуку як активну речовину і цукровий спирт
GB2416981A (en) 2004-08-13 2006-02-15 Nutraceuticals Ltd Premixes, flour enriched with same, mineral supplemented foodstuffs and methods of manufacture therefore.
US7862836B2 (en) * 2005-04-12 2011-01-04 Biolink Life Sciences, Inc. Phosphorus binder for treatment of kidney disease
ES2382993T3 (es) 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio

Also Published As

Publication number Publication date
WO2008011126A2 (fr) 2008-01-24
KR20090040340A (ko) 2009-04-23
EP2048948B1 (fr) 2012-02-29
BRPI0714882A2 (pt) 2013-05-21
RU2463060C2 (ru) 2012-10-10
CA2658465C (fr) 2016-06-14
CN104095838A (zh) 2014-10-15
US20110251282A1 (en) 2011-10-13
US8591938B2 (en) 2013-11-26
CN101522021A (zh) 2009-09-02
HK1202815A1 (en) 2015-10-09
IL196584A0 (en) 2009-11-18
JP5335674B2 (ja) 2013-11-06
AU2007275606B9 (en) 2013-09-26
PL2484352T3 (pl) 2014-12-31
AU2007275606B2 (en) 2013-06-06
NZ574331A (en) 2011-01-28
US20140255515A1 (en) 2014-09-11
KR101553719B1 (ko) 2015-09-16
ATE547099T1 (de) 2012-03-15
JP2009544615A (ja) 2009-12-17
ES2382993T3 (es) 2012-06-15
AU2007275606A1 (en) 2008-01-24
EP2048948A2 (fr) 2009-04-22
EP2484352A1 (fr) 2012-08-08
CN101522021B (zh) 2014-07-30
RU2009104774A (ru) 2010-08-20
US8592480B2 (en) 2013-11-26
CA2658465A1 (fr) 2008-01-24
EP2484352B1 (fr) 2014-07-09
WO2008011126A3 (fr) 2008-09-18
EP2048948A4 (fr) 2009-11-11
US9089528B2 (en) 2015-07-28
PL2048948T3 (pl) 2012-07-31
MX2009000722A (es) 2009-06-11
US20080021104A1 (en) 2008-01-24
HK1129814A1 (en) 2009-12-11

Similar Documents

Publication Publication Date Title
IL196584A0 (en) Liquid compositions of calcium acetate
WO2007117778A8 (fr) Quinolones utiles en tant qu'inhibiteurs de l'oxyde nitrique synthase inductible
WO2005075425A3 (fr) Derives de bisaryluree
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2009153665A3 (fr) Inhibiteurs des toxines shiga circulant dans la voie de transport rétrograde
TW200612892A (en) Novel compounds
WO2008144346A3 (fr) Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation
WO2009027820A3 (fr) Composés de pipéridine de type quinoxaline substituée et leurs utilisations
WO2008011364A3 (fr) Compositions contenant de la quercétine
WO2007135241A3 (fr) Composition et méthode de liaison de l'acétaldéhyde dans l'estomac
WO2008017346A3 (fr) Utilisation de dérivés d'acide ascorbique pour la fonctionnalisation de matrices
WO2007036363A3 (fr) Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
TW200630336A (en) Novel compounds
WO2007052023A3 (fr) Composes
TW200621690A (en) Novel compounds
WO2007144778A3 (fr) Compositions à base de plantes pour la prévention ou le traitement d'une infection des voies urinaires
WO2009100275A3 (fr) Compositions et dispositifs
WO2012075015A3 (fr) Compositions pharmaceutiques orales de métronidazole
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2010121213A3 (fr) Compositions antibactériennes
WO2008033935A3 (fr) Dérivés de la vinorelbine
WO2007104933A8 (fr) Composés chimiques
SG169979A1 (en) Accelerating agent of calcium absorption